

From the Bench to Bedside Clinical Decision Support:

The Role of Semantic Technologies in a Knowledge Management Infrastructure for Translational Medicine

Tonya Hongsermeier, MD, MBA
Corporate Manager, Clinical Knowledge Management and Decision Support
Clinical Informatics R&D
Partners Healthcare System

Current State of Translational Medicine

- 17 year innovation adoption curve from discovery into accepted standards of practice
- Even if a standard is accepted, patients have a 50:50 chance of receiving appropriate care, a 5-10% probability of incurring a preventable, anticipatable adverse event
- The market is balking at healthcare inflation, new diagnostics and therapeutics will find increasing resistance for reimbursement
- Most EHRs are under-nourished with knowledge, knowledge is embedded in multiple disconnected legacy pools and difficult to maintain, EHR knowledge editors are primitive and disconnected from semantics
- Volume/velocity of knowledge processing exponentially growing, today we run at most 1000 rules at run time to manage an encounter, tomorrow, we'll need to answer 1000,000s of questions for every decision

The Cytochrome P450 test...
new data to drive drug choice and dose
When do you order this test?
How do you use the test result?




Leading the News: Roche Test Promises to Tailor Drugs to Patients --- Precise Genetic Approach Could Mean Major Changes In Development, Treatment

June 25, 2003

Roche Holding AG is launching the first gene test able to predict how a person will react to a large range of commonly prescribed medicines, one of the biggest forays yet into tailoring drugs to a patient's genetic makeup. The test is part of an emerging approach to treatment that health experts expect could lead to big changes in the way drugs are developed, marketed and prescribed. For all of the advances in medicine, doctors today determine the best medicine and dose for an ailing patient largely by trial and error. The fast-growing field of "personalized" medicine hopes to remove such risks and alter the pharmaceutical industry's more one-size-fits-all approach in making and selling drugs.




Closing the Loop on Decision Support and Discovery Depends on Shared Semantics



Role of Semantic Technologies in Healthcare and Lifesciences

- Data/Knowledge Integration and Visualization
 - Ontology based approaches
 - Integration across multiple data sources:
 - Genotypic/Phenotypic data from LIMS/HER
 - Knowledge Repositories for data interpretation
- Clinical Decision Support
 - Inference engines - SWRL
 - Description logics for "recognition" - OWL
 - Knowledge representation
 - Etc.
- Knowledge Acquisition, Maintenance and Evolution
 - Ontology-based Definitions Management
 - Versioning, life-cycle, propagation into "dependent" objects such as rules, templates orders/documentation, reporting systems
 - Knowledge Provenance
 - Reconciling knowledge representation among different stakeholders (care givers, payors, performance measurement, clinical trials, R&D)

EGFR epidermal growth factor receptor gene



Laboratory for Molecular Medicine > Tests

OVERVIEW TESTS ORDERING PAYMENT RESEARCH RESOURCES

EGFR Sequencing Test

The LMM performs bi-directional sequence analysis of the kinase domain of the *EGFR* gene as a clinical test to help predict tumor response to tyrosine kinase inhibitors. The LMM has the limited right to offer *EGFR* mutation testing solely to patients of Massachusetts General Hospital (MGH), Dana-Farber Cancer Institute (DFCI) and Brigham and Women's Hospital (BWH). Genzyme Corporation is the exclusive provider of *EGFR* mutation testing for all other institutions.

Background

The epidermal growth factor receptor gene, *EGFR*, encodes a receptor tyrosine kinase, and is the target of tyrosine kinase inhibitors (TKIs). In three separate studies, somatic mutations in the kinase domain of *EGFR* were associated with improved response to TKIs.

EGFR GENE SEQUENCING TEST


Gene: *EGFR* at 7p12.3-p12.1

Methodology: Bi-directional DNA sequencing of 7 exons (18-24) and splice sites

Clinical Sensitivity: Variable

- Indicates responsiveness of Non-Small Cell Lung Cancer (NSCLC) to Tyrosine Kinase Inhibitors (TKIs)
- Tarceva and Iressa

Clinical processes for EGFR Testing



Business Rule: EGFR - TKI Indication

General Information
Name: GFR
Categories: Any

Documentation
IF patient has <Test Result: EGFR Mutation> value=<Non-responder> THEN update <Patient Clinical State> = TKI non-responder

Code
Today, we represent the algorithms as Business rules....

TKI Inhibitors – Knowledge-change Event Management

- Ongoing research means interpretation of EGFR test result will have continuously changing clinical significance
- Must model which changes warrant notification to change clinical management (new kind of classification rule)
- Must propagate these knowledge base changes into Rules, Documentation Templates and Quality and Safety Reporting Systems

Warning	
You are ordering: Tarceva	
Drug – Genetic Intervention	
Alert Message	Keep New Order – selected
TARCEVA is contraindicated in patients with a somatic EGFR mutation known to be associated with resistance to Tyrosine Kinase Inhibitors for treatment of non-small cell lung cancer. Most recent = <overallResult> <date>	Reasons for override: <input type="checkbox"/> Patient has pancreatic cancer <input type="checkbox"/> No reasonable alternatives <input type="checkbox"/> Other _____

Knowledge Acquisition, Propagation and Change Management

- Our approach is to build a knowledge staging infrastructure that enables knowledge-base change to propagate across related areas,
- Will be leveraging Semantic Web Technologies to deploy knowledge as ontologies in encapsulated, re-usable services to avoid knowledge replication where possible to reduce cost the of maintenance
- EHR vendor community will need to address gaps in their infrastructure approach to knowledge acquisition or it will be impossible to meet requirements of Personalized Medicine

